CN110740996B - 共价小分子dcn1抑制剂和使用其的治疗方法 - Google Patents
共价小分子dcn1抑制剂和使用其的治疗方法 Download PDFInfo
- Publication number
- CN110740996B CN110740996B CN201880038225.2A CN201880038225A CN110740996B CN 110740996 B CN110740996 B CN 110740996B CN 201880038225 A CN201880038225 A CN 201880038225A CN 110740996 B CN110740996 B CN 110740996B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- compound
- dcn1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483640P | 2017-04-10 | 2017-04-10 | |
| US62/483,640 | 2017-04-10 | ||
| PCT/US2018/026789 WO2018191199A1 (en) | 2017-04-10 | 2018-04-10 | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110740996A CN110740996A (zh) | 2020-01-31 |
| CN110740996B true CN110740996B (zh) | 2024-01-09 |
Family
ID=62067873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880038225.2A Active CN110740996B (zh) | 2017-04-10 | 2018-04-10 | 共价小分子dcn1抑制剂和使用其的治疗方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10500194B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3609876B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7086171B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110740996B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018251687B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059256C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2916449T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018191199A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| WO2019043214A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | glutarimide |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| EP3883597A2 (en) * | 2018-11-20 | 2021-09-29 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| EP3938050A1 (en) | 2019-03-15 | 2022-01-19 | Fulcrum Therapeutics, Inc. | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| AU2021397774A1 (en) * | 2020-12-10 | 2023-06-29 | Adgero Biopharmaceuticals Holdings, Inc. | Methods for treating cutaneous metastatic cancers |
| CN112830957B (zh) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | 一种制备卡非佐米的方法 |
| WO2023059605A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| AU2023283735A1 (en) | 2022-06-06 | 2024-10-31 | C4 Therapeutics, Inc. | Bicyclic-substituted glutarimide cereblon binders |
| CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
| WO2025096956A1 (en) | 2023-11-03 | 2025-05-08 | Cellarity, Inc. | Dcn-1 modulating compounds and methods of use thereof |
| WO2025096981A1 (en) | 2023-11-03 | 2025-05-08 | Cellarity, Inc. | Modulators of dcn-1 and methods of use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049165A (zh) * | 1989-06-29 | 1991-02-13 | 沃纳-兰伯特公司 | N-取代的环烷基和多环烷基α-取代的色氨酸-苯丙氨酸-和苯乙胺衍生物 |
| WO2017049295A1 (en) * | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
-
2018
- 2018-04-10 AU AU2018251687A patent/AU2018251687B2/en active Active
- 2018-04-10 JP JP2020504290A patent/JP7086171B2/ja active Active
- 2018-04-10 ES ES18720910T patent/ES2916449T3/es active Active
- 2018-04-10 US US15/949,799 patent/US10500194B2/en active Active
- 2018-04-10 WO PCT/US2018/026789 patent/WO2018191199A1/en not_active Ceased
- 2018-04-10 CA CA3059256A patent/CA3059256C/en active Active
- 2018-04-10 EP EP18720910.1A patent/EP3609876B1/en active Active
- 2018-04-10 CN CN201880038225.2A patent/CN110740996B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1049165A (zh) * | 1989-06-29 | 1991-02-13 | 沃纳-兰伯特公司 | N-取代的环烷基和多环烷基α-取代的色氨酸-苯丙氨酸-和苯乙胺衍生物 |
| WO2017049295A1 (en) * | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
Non-Patent Citations (1)
| Title |
|---|
| A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation;Haibin Zhou et al.;《NATURE COMMUNICATIONS》;20171027;第8卷(第1期);第1-12页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2916449T3 (es) | 2022-07-01 |
| US10500194B2 (en) | 2019-12-10 |
| CA3059256A1 (en) | 2018-10-18 |
| US20180289677A1 (en) | 2018-10-11 |
| JP7086171B2 (ja) | 2022-06-17 |
| EP3609876B1 (en) | 2022-03-30 |
| JP2020516679A (ja) | 2020-06-11 |
| CA3059256C (en) | 2024-04-16 |
| CN110740996A (zh) | 2020-01-31 |
| AU2018251687A1 (en) | 2019-10-24 |
| EP3609876A1 (en) | 2020-02-19 |
| WO2018191199A1 (en) | 2018-10-18 |
| AU2018251687B2 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110740996B (zh) | 共价小分子dcn1抑制剂和使用其的治疗方法 | |
| US12012467B2 (en) | Small molecule DCN1 inhibitors and therapeutic methods using the same | |
| JP6873980B2 (ja) | ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体 | |
| EP2888265B1 (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| JP5642777B2 (ja) | Ｉａｐ阻害剤 | |
| CA3033239A1 (en) | Spiro bicyclic inhibitors of menin-mll interaction | |
| CN110291084A (zh) | 用于治疗癌症的组合物和方法 | |
| MXPA06014969A (es) | Inhibidores de iap. | |
| KR20190045242A (ko) | 메닌-mll 상호작용의 스피로 바이사이클릭 억제제 | |
| TW200412966A (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CN102458115B (zh) | Iap抑制剂 | |
| EP1899346B1 (en) | Pyrrolotriazine compounds useful as kinase inhibitors | |
| EP2651949B1 (en) | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway | |
| CA3119882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| EP1899345B1 (en) | Pyrrolotriazine compounds useful as kinase inhibitors | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| JP2025508328A (ja) | 抗体にコンジュゲートした化学的分解誘導物質とその方法 | |
| HK40005133A (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| HK40006375A (en) | Bivalent inhibitors of iap proteins and therapeutic methods using the same | |
| HK40013658A (en) | Compositions and methods for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |